Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Item 1.01 Entry Into a Material Definitive Agreement On 4 June 2026 (Sydney time), EBR Systems, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with several underwriters for a fully underwritten A$150.0 million capital raise (the “Placement”) through the sale of CHESS Depository Interests (“CDIs”) in the approximate amount of 394.7 million new CDIs (“New…
Filed Jun 10, 2026Accepted Jun 10, 2026, 3:44 PM EDTCIK 1347123Accession 0001214659-26-007314
Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry Into a Material Definitive Agreement
On
4 June 2026 (Sydney time), EBR Systems, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting
Agreement”) with several underwriters for a fully underwritten A$150.0 million capital raise (the “Placement”)
through the sale of CHESS Depository Interests (“CDIs”) in the approximate amount of 394.7 million new CDIs
(“New CDIs”), with every ten (10) CDIs representing one share of the Company’s common stock, to institutional
investors on the Australian Securities Exchange (“ASX”) through (i) a fully underwritten institutional placement
to institutional and sophisticated investors to raise approximately A$64.4 million (the “Institutional Placement”),
comprising (a) A$29.4 million institutional placement to institutional and sophisticated investors (“Tranche 1 Placement”);
and (b) A$35.0 million conditional placement, placed to existing securityholders, subject to securityholder approval (“Tranche
2 Placement”), and (ii) a fully underwritten 1 for 2 pro rata accelerated non-renounceable entitlement offer to raise approximately
A$85.6 million (the “Entitlement Offer”).
On
5 June 2026 (Sydney time), the Company successfully completed the Institutional Placement in the amount of approximately A$64.4 million,
consisting of the Tranche 1 Placement, which does not require securityholder approval, and the Tranche 2 Placement, which is subject to
securityholder approval at a special meeting of the securityholders. The Company also successfully completed the institutional component
of the Entitlement Offer (the “Institutional Entitlement Offer”), which raised gross proceeds of A$42.0 million,
with a take up of approximately A$8.4 million by eligible institutional securityholders and the remainder of the institutional entitlements
being approximately A$33.6 million, including New CDIs not taken up by foreign ineligible securityholders, placed to eligible institutional
and sophisticated investors as part of the bookbuild.
The
Tranche 1 Placement and the Institutional Entitlement Offer is expected to settle on Thursday, 11 June 2026 (Sydney time). The Tranche
2 Placement, which is subject to securityholder approval at a meeting of the securityholders, is expected to settle in August 2026. The
portion of the Entitlement Offer allocated for eligible retail securityholders with a registered address in Australia or New Zealand as
of the record date of 7:00pm (Sydney time) on Friday, 5 June 2026 (the “Retail Entitlement Offer”), will raise
a further A$43.6 million and will open on Thursday, 11 June 2026 (Sydney time).
The
offer price per New CDI was A$0.38, which represents (i) a 19.1% discount to the last closing price of the Company’s CDIs on 3 June
2026 (Sydney time) being A$0.47, (ii) a 15.6% discount to the 5-day VWAP up to 3 June 2026 (Sydney time) being A$0.450, and (iii) a 11.2%
discount to the theoretical ex-rights price of A$0.428 per CDI.
Canaccord
Genuity (Australia) Limited, E&P Capital Limited and Morgans Corporate Limited acted as joint underwriters, joint lead managers and
joint book runners for the Institutional Placement and Entitlement Offer.
The
Underwriting Agreement contains customary representations, warranties, and covenants by the parties, including certain indemnification
obligations. The representations, warranties, and covenants contained in the Underwriting Agreement were made only for purposes of such
agreement and as of specific dates, were solely for the benefit of the parties and are subject to limitations agreed upon in it. Accordingly,
the Underwriting Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Institutional
Placement and Entitlement Offer and not to provide investors with any other factual information regarding the Company or its business
and should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the Securities and
Exchange Commission.
The
foregoing description of the Underwriting Agreement is not complete and is qualified in its entirety by reference to the full text of
the Underwriting Agreement, which is filed herewith as Exhibit 10.1 and incorporated herein by reference in its entirety.
Item 3.02Item 3.02 - Unregistered Sales of Equity
Item 3.02 Recent Sales of Unregistered Securities
To the
extent required by Item 3.02 of Form 8-K, the information regarding the New CDIs and common stock sold in the Placement set forth under
Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 3.02. The securities issued and sold in the Placement
were deemed to be exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”)
in reliance on Regulation S promulgated under the Securities Act, as transactions by an issuer in an offering made outside the United
States. Appropriate legends or notices were affixed to the securities issued in reliance on Regulation S to ensure compliance with Regulation
S restrictions.